GABA-producing bacteria for improving health patent application

This document is a patent application (US20260083786A1) filed with the USPTO, disclosing a composition containing the isolated bacteria Lactobacillus brevis (NCIMB 41903). The application, filed on September 17, 2025, by inventors Paul Ross and Catherine Stanton, claims its use in a method for regulating or treating metabolic diseases or their symptoms.

As a patent application, this document does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future intellectual property and market exclusivity for specific therapeutic applications of this bacterial strain. Companies in the pharmaceutical and food manufacturing sectors should be aware of this filing as it may impact future product development and competitive landscapes in the area of metabolic health treatments.